Dannehl, D.; Volmer, L.L.; Weiss, M.; Matovina, S.; Grischke, E.-M.; Oberlechner, E.; Seller, A.; Walter, C.B.; Hahn, M.; Engler, T.;
et al. Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center. J. Pers. Med. 2022, 12, 382.
https://doi.org/10.3390/jpm12030382
AMA Style
Dannehl D, Volmer LL, Weiss M, Matovina S, Grischke E-M, Oberlechner E, Seller A, Walter CB, Hahn M, Engler T,
et al. Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center. Journal of Personalized Medicine. 2022; 12(3):382.
https://doi.org/10.3390/jpm12030382
Chicago/Turabian Style
Dannehl, Dominik, Lea L. Volmer, Martin Weiss, Sabine Matovina, Eva-Maria Grischke, Ernst Oberlechner, Anna Seller, Christina B. Walter, Markus Hahn, Tobias Engler,
and et al. 2022. "Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center" Journal of Personalized Medicine 12, no. 3: 382.
https://doi.org/10.3390/jpm12030382
APA Style
Dannehl, D., Volmer, L. L., Weiss, M., Matovina, S., Grischke, E.-M., Oberlechner, E., Seller, A., Walter, C. B., Hahn, M., Engler, T., Brucker, S. Y., & Hartkopf, A. D.
(2022). Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center. Journal of Personalized Medicine, 12(3), 382.
https://doi.org/10.3390/jpm12030382